Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Vitiligo Study

Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Adult and Adolescent Participants with Non-Segmental Vitiligo

Psoriasis on elbow


AGE: 18+ years old
TYPE: Interventional Study
LOCATION: University Hospitals Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Kymberlyn Warner King at 216-844-7546 or complete the form below.

Study Purpose

The purpose of the study is to evaluate whether the study drug, Ritlecitinib, is effective in managing vitiligo and if it is safe for human use. The study drug will be compared with a placebo, a study drug that does not contain any active ingredients, to find out if the study drug is better than the placebo for the study treatment of vitiligo.

Who Can Participate

Participants 18 years and older diagnosed with non-segmental vitiligo may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot